Know Cancer

forgot password

The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

Phase 2
18 Years
Not Enrolling
Multiple Myeloma

Thank you

Trial Information

The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

20 patients will be included in the study over a 2 year period. Before, during and after
treatment we will measure NTX-I, CTX-I, CTX-MMP, bALP, DKK-1, PINP, TRAcP and PTH. NTX, CTX
and CTX-MMP are measured to estimate bone degradation. TRAcP is measured to estimate the
activity of the osteoclasts. bALP and DKK-1 is measured to evaluate the activity of the
osteoblasts and PINP is measured as a marker of new bone formation. PTH is measured in order
to evaluate if the positive effects that is observed in bone formation in relations to
velcade treatment is due to the pulsative way velcade is administered.

The effect of the velcade treatment will be evaluated by x-ray, bone marrow and m-component.

Inclusion Criteria:

- Previously untreated multiple myeloma

Exclusion Criteria:

- Use of bisfosfonates

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Changes in bone markers during treatment

Principal Investigator

Torben Plesner, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Vejle Hospital


Denmark: Danish Medicines Agency

Study ID:




Start Date:

February 2007

Completion Date:

July 2009

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Bone Marrow Neoplasms